CeriBell (CBLL) Projected to Post Earnings on Monday

CeriBell (NASDAQ:CBLL) is anticipated to post its Q1 2026 results after the market closes on Monday, May 11th. Analysts expect CeriBell to post earnings of ($0.39) per share and revenue of $26.0860 million for the quarter. Individuals may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Monday, May 11, 2026 at 4:30 PM ET.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings data on Tuesday, February 24th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.07. CeriBell had a negative net margin of 59.97% and a negative return on equity of 31.77%. The business had revenue of $24.78 million during the quarter, compared to analyst estimates of $23.95 million. On average, analysts expect CeriBell to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

CeriBell Stock Up 1.7%

Shares of NASDAQ CBLL traded up $0.34 during midday trading on Monday, hitting $20.84. The company’s stock had a trading volume of 17,426 shares, compared to its average volume of 306,442. The business’s fifty day simple moving average is $19.15 and its two-hundred day simple moving average is $18.55. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.73 and a quick ratio of 9.35. CeriBell has a 1 year low of $10.85 and a 1 year high of $24.33. The firm has a market capitalization of $789.17 million, a price-to-earnings ratio of -14.01 and a beta of 0.99.

Insiders Place Their Bets

In other news, CEO Xingjuan Chao sold 39,000 shares of the stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $18.40, for a total value of $717,600.00. Following the transaction, the chief executive officer owned 850,347 shares in the company, valued at approximately $15,646,384.80. This represents a 4.39% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Josef Parvizi sold 16,714 shares of the firm’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $20.27, for a total value of $338,792.78. Following the sale, the director directly owned 722,652 shares in the company, valued at $14,648,156.04. This trade represents a 2.26% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 130,571 shares of company stock valued at $2,411,026 in the last three months. Corporate insiders own 20.10% of the company’s stock.

Hedge Funds Weigh In On CeriBell

Hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its holdings in CeriBell by 11.1% during the third quarter. Vanguard Group Inc. now owns 1,473,856 shares of the company’s stock worth $16,935,000 after purchasing an additional 147,013 shares in the last quarter. Yu Fan boosted its holdings in shares of CeriBell by 10.7% in the 2nd quarter. Yu Fan now owns 1,353,166 shares of the company’s stock valued at $25,345,000 after buying an additional 130,964 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of CeriBell by 1,945.9% in the 4th quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock valued at $26,797,000 after buying an additional 1,162,200 shares in the last quarter. KCM Capital Inc acquired a new position in shares of CeriBell in the 4th quarter valued at $21,930,000. Finally, Novo Holdings A S boosted its holdings in shares of CeriBell by 2.3% in the 2nd quarter. Novo Holdings A S now owns 900,000 shares of the company’s stock valued at $16,857,000 after buying an additional 20,000 shares in the last quarter.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of CeriBell in a research note on Monday, April 6th. BTIG Research reissued a “buy” rating and issued a $30.00 price objective on shares of CeriBell in a research note on Wednesday, January 28th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, CeriBell presently has a consensus rating of “Moderate Buy” and an average target price of $23.20.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.